These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 2032232)

  • 21. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
    Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.
    Fram RJ; Woda BA; Wilson JM; Robichaud N
    Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.
    Swinnen LJ; Barnes DM; Fisher SG; Albain KS; Fisher RI; Erickson LC
    Cancer Res; 1989 Mar; 49(6):1383-9. PubMed ID: 2924295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells.
    Farrell N; Povirk LF; Dange Y; DeMasters G; Gupta MS; Kohlhagen G; Khan QA; Pommier Y; Gewirtz DA
    Biochem Pharmacol; 2004 Sep; 68(5):857-66. PubMed ID: 15294448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ; Friedlos F; Lydall DA; Roberts JJ
    Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
    Kido Y; Khokhar AR; al-Baker S; Siddik ZH
    Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity and cross-resistance studies with Pt-ascorbato complexes.
    Hrubisko M; Balázová E; Kiss F; Kovácová J; Ujházy V
    Neoplasma; 1989; 36(6):651-7. PubMed ID: 2615869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).
    Holford J; Raynaud F; Murrer BA; Grimaldi K; Hartley JA; Abrams M; Kelland LR
    Anticancer Drug Des; 1998 Jan; 13(1):1-18. PubMed ID: 9474239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and -resistant adenocarcinoma cells.
    Talarico T; Cullinane CM; Gray PJ; Webster LK; Deacon GB; Phillips DR
    Anticancer Drug Des; 2001; 16(2-3):135-41. PubMed ID: 11962511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of cis-diamminedichloroplatinum (II) on the formation of DNA-Pt-DNA cross-links.
    Walter Z; Spychała M
    Acta Biochim Pol; 1991; 38(1):95-9. PubMed ID: 1796714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients.
    Terheggen PM; Dijkman R; Begg AC; Dubbelman R; Floot BG; Hart AA; den Engelse L
    Cancer Res; 1988 Oct; 48(19):5597-603. PubMed ID: 3046743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
    Roberts JJ; Friedlos F
    Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes.
    Buckley RG; Elsome AM; Fricker SP; Henderson GR; Theobald BR; Parish RV; Howe BP; Kelland LR
    J Med Chem; 1996 Dec; 39(26):5208-14. PubMed ID: 8978849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents.
    Montine TJ; Borch RF
    Cancer Res; 1988 Nov; 48(21):6017-24. PubMed ID: 2458831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.